Opendata, web and dolomites

TruVue

A novel and easy to interpret patient safety monitor, for the diagnosis and management of cardiac function, fluid delivery and drug administration during surgery and intensive care.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TruVue project word cloud

Explore the words cloud of the TruVue project. It provides you a very rough idea of what is the project "TruVue" about.

aortic    undergo    truvue    complications    business    return    contribution    adverse    care    meet    provides    paris    trial    flow    hospital    51    interface    ce    serious    healthcare    myocardial    centres    seed    opportunity    faces    multicentre    obtain    interaction    clinical    simply    monitors    lifespan    failing    million    stroke    42    mortality    unplanned    haemodynamic    multinational    worldwide    thousands    infarctions    instability    costed    readmissions    diagnostic    234    simultaneous    frequent    monitoring    patients    visual    ages    injury    velocity    sales    input    situation    envisages    events    population    2020    graphical    fold    longer    annually    surgery    presented    errors    generate    loops    sooner    kidney    unacceptable    days    plan    financial    reduce    publications    uses    13    deltex    revenues    shorter    stay    save    outcomes    protecting    safety    pressure    lives    day    die    discharge    hemodynamic    globally    patient    marked    enter    gui    inadequate    full    investment    truly    admissions    lariboisiere    blood    intensive    12    display   

Project "TruVue" data sheet

The following table provides information about the project.

Coordinator
DELTEX MEDICAL LIMITED 

Organization address
address: TERMINUS ROAD
city: CHICHESTER
postcode: PO19 8TX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.deltexmedical.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2017-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DELTEX MEDICAL LIMITED UK (CHICHESTER) coordinator 50˙000.00

Map

 Project objective

Worldwide 234 million patients undergo major surgery annually. One million will die within 30 days. A further 42 million simply die up to 13 years sooner due to complications and 12 million will enter intensive care in the EU and US. This unacceptable situation has the potential to increase Deltex’s revenues 5 fold by 2020 through the development of TruVue. Of the adverse events 51% are directly due to inadequate haemodynamic management. Hemodynamic instability and low blood pressure are frequent, with consequences such as myocardial infarctions, stroke and kidney injury. Complications have serious clinical and financial consequences; unplanned intensive care admissions; longer stay; increased readmissions; increased 30 day mortality; and shorter patient lifespan after discharge. Healthcare faces increasingly complex cases as the population ages and uses ever more complex equipment. Protecting patients from haemodynamic errors through improved monitoring should save thousands of lives, improve outcomes and reduce costs. Diagnostic haemodynamic equipment needs to display the interaction of flow and pressure if it is to be truly effective. Current monitors are failing to meet this need. Deltex and Lariboisiere Hospital Paris have developed the novel TruVue Velocity Pressure Loops system. TruVue provides simultaneous visual display of the patient’s aortic blood flow velocity and aortic blood pressure; and will be a significant contribution to patient safety. TruVue has been CE-marked and is in use at Lariboisiere Hospital. This phase 1 project has two aims: to obtain user input to enhance the Graphical User Interface (GUI); and to cost a multinational multicentre clinical trial for phase 2 application. Deltex envisages that the clinical trial will generate publications, ‘seed’ leading centres and promote the TruVue within the EU and globally. A full assessment of the sales opportunity and return on investment will be presented as part of a fully-costed business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRUVUE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRUVUE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

REALM (2015)

A disruptive method to free physicians from Hospital Information Systems by generating fault free patient diagnostic documents in real-time using natural language

Read More  

SOFT (2017)

SOFT, the first camera-based colorectal cancer screening test to detect occult blood in faeces immediately and with no lab analysis.

Read More  

HUMEXE (2017)

HUman EXoskEleton

Read More